Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Debt to Equity: 2013-2024

Historic Debt to Equity for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $0.82.

  • Amphastar Pharmaceuticals' Debt to Equity fell 4.31% to $0.78 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.78, marking a year-over-year decrease of 4.31%. This contributed to the annual value of $0.82 for FY2024, which is 10.93% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Debt to Equity of $0.82 as of FY2024, which was down 10.93% from $0.92 recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Debt to Equity ranged from a high of $0.92 in FY2023 and a low of $0.10 during FY2020.
  • Its 3-year average for Debt to Equity is $0.63, with a median of $0.82 in 2024.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Debt to Equity decreased by 16.92% in 2022 and then skyrocketed by 542.83% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Debt to Equity (MRY) stood at $0.10 in 2020, then surged by 66.92% to $0.17 in 2021, then dropped by 16.92% to $0.14 in 2022, then soared by 542.83% to $0.92 in 2023, then fell by 10.93% to $0.82 in 2024.
  • Its Debt to Equity was $0.82 in FY2024, compared to $0.92 in FY2023 and $0.14 in FY2022.